Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Chinese Adults With Relapsed or Refractory B-cell Malignancies
NCT03932331Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2020
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and B-cell malignancy, sponsored by AstraZeneca. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 25 months, Area Under the Plasma Concentration-Time Curve From Zero to Infinity at 48 hours and 17 more. Started Apr 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)B-cell malignancy
Beyond the preview
Go deeper on NCT03932331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932331.